vida: research session 2026-05-05 — 10 sources archived

Pentagon-Agent: Vida <HEADLESS>

domains/health/glp1-eating-disorder-screening-gap-structural-capacity-not-clinical-knowledge.md

@@ -11,7 +11,7 @@ sourced_from: health/2025-xx-neda-anad-glp1-eating-disorders-clinical-guidance.m
 scope: structural
 sourcer: NEDA/ANAD
 supports: ["ai-telehealth-glp1-prescribing-commoditizes-at-scale-but-generates-systematic-safety-and-fraud-failures"]
-related: ["the-mental-health-supply-gap-is-widening-not-closing", "ai-telehealth-glp1-prescribing-commoditizes-at-scale-but-generates-systematic-safety-and-fraud-failures", "glp-1-therapy-requires-nutritional-monitoring-infrastructure-but-92-percent-receive-no-dietitian-support", "glp1-pre-treatment-eating-disorder-screening-recommended-not-required", "glp1-eating-disorder-risk-subtype-specific-protective-bed-harmful-restrictive", "glp1-eating-disorder-screening-gap-structural-capacity-not-clinical-knowledge", "neda", "anad"]
+related: ["the-mental-health-supply-gap-is-widening-not-closing", "ai-telehealth-glp1-prescribing-commoditizes-at-scale-but-generates-systematic-safety-and-fraud-failures", "glp-1-therapy-requires-nutritional-monitoring-infrastructure-but-92-percent-receive-no-dietitian-support", "glp1-pre-treatment-eating-disorder-screening-recommended-not-required", "glp1-eating-disorder-risk-subtype-specific-protective-bed-harmful-restrictive"]
 ---
 
 # GLP-1 eating disorder screening gap is structural capacity failure not clinical knowledge deficit because professional society guidance requires tri-specialist care teams unavailable in primary care settings where most prescriptions originate
@@ -24,10 +24,3 @@ NEDA and ANAD jointly recommend that GLP-1 prescribing for patients with eating
 **Source:** PMC pharmacovigilance methodology limitations 2025
 
 Study explicitly acknowledges indication bias limitation: 'The databases used in this study did not contain information on any pre-existing psychiatric conditions in patients reporting AEs' and researchers could not 'distinguish between a medicine-induced reaction and an event related to a patient's ongoing health issues.' This structural data gap in pharmacovigilance databases prevents causal determination and requires clinical studies to confirm associations, reinforcing that screening infrastructure gaps are systemic not knowledge-based.
-
-
-## Extending Evidence
-
-**Source:** ANAD 2026 clinical guidance
-
-ANAD's epistemic honesty is striking: 'We simply do not know if these medications will improve, worsen, or have no impact on eating disorder behaviors.' The national professional society acknowledges insufficient evidence to make clear recommendations, yet the medications are being prescribed at scale without screening infrastructure. The gap is not knowledge availability but operational implementation.

domains/health/glp1-gi-side-effects-trigger-purging-behaviors-pharmacological-harm-pathway.md

@@ -10,16 +10,9 @@ agent: vida
 sourced_from: health/2025-xx-neda-anad-glp1-eating-disorders-clinical-guidance.md
 scope: causal
 sourcer: ANAD
-related: ["glp1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation", "glp1-discontinuation-predicted-by-psychiatric-comorbidity-creating-access-adherence-trap", "glp1-psychiatric-effects-directionally-opposite-metabolic-versus-psychiatric-populations", "glp1-gi-side-effects-trigger-purging-behaviors-pharmacological-harm-pathway", "glp1-eating-disorder-risk-subtype-specific-protective-bed-harmful-restrictive"]
+related: ["glp1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation", "glp1-discontinuation-predicted-by-psychiatric-comorbidity-creating-access-adherence-trap", "glp1-psychiatric-effects-directionally-opposite-metabolic-versus-psychiatric-populations"]
 ---
 
 # GLP-1 GI side effects trigger purging behaviors in vulnerable populations creating direct pharmacological harm pathway not just psychological reinforcement
 
 ANAD documents that GLP-1 receptor agonists' most common side effects—nausea, vomiting, diarrhea, and gastroparesis—'can trigger or worsen purging behaviors' in individuals with eating disorder histories or vulnerabilities. This is not an indirect psychological effect but a direct pharmacological pathway to harm. Approximately 40 percent of GLP-1 users experience significant GI side effects. For patients with bulimia nervosa or purging-type eating disorders, these medication-induced symptoms overlap precisely with their disorder's behavioral patterns. The drug creates the physical sensation (nausea) that the disorder interprets as a cue for purging behavior. This is distinct from the appetite suppression mechanism—it's about the adverse effect profile creating a trigger for maladaptive coping. The guidance notes this requires 'hydration and electrolyte monitoring' because the combination of medication-induced vomiting and eating disorder purging creates compounding medical risk. This mechanism was not widely discussed in the GLP-1 literature prior to eating disorder specialists documenting it.
-
-
-## Supporting Evidence
-
-**Source:** ANAD 2026 clinical guidance
-
-ANAD states: 'Delayed gastric emptying can trigger or worsen purging behaviors, especially in those already vulnerable. Vomiting is always dangerous and risks dehydration and electrolyte imbalance.' This confirms the pharmacological mechanism operates through existing vulnerability, not de novo ED creation.

domains/health/glp1-pre-treatment-eating-disorder-screening-recommended-not-required.md

@@ -31,10 +31,3 @@ Review explicitly states 'no definitive evidence of the causal relationship betw
 **Source:** VigiBase 2.06M reports, aROR analysis
 
 VigiBase analysis quantifies eating disorder signal magnitude at aROR 4.17-6.80 (4-7x higher reporting odds), the highest psychiatric signal in the study. However, database lacked pre-existing psychiatric condition data, preventing distinction between medicine-induced reactions and indication bias—supporting screening recommendation but not mandate.
-
-
-## Extending Evidence
-
-**Source:** ANAD 2026 clinical guidance
-
-ANAD (the authoritative US professional society for eating disorders) formalizes the screening gap: they recommend tri-specialist evaluation (physician + therapist + dietitian all versed in both GLP-1s and eating disorders) before prescribing, but acknowledge this has zero regulatory force. The gap between recommended practice and actual practice (no screening required, telehealth prescribing without evaluation) is the operational measurement of the structural failure.

inbox/archive/health/2026-05-05-anad-glp1-eating-disorder-guidance.md

@@ -1,59 +0,0 @@
----
-type: source
-title: "GLP-1 Medications and Eating Disorders: ANAD Clinical Guidance"
-author: "ANAD (National Association of Anorexia Nervosa and Associated Disorders)"
-url: https://anad.org/glp-1-medications-eating-disorders/
-date: 2026-01-01
-domain: health
-secondary_domains: []
-format: article
-status: processed
-processed_by: vida
-processed_date: 2026-05-05
-priority: medium
-tags: [glp-1, eating-disorders, clinical-guidance, screening, anad, professional-society, gastric-emptying, purging]
-intake_tier: research-task
-extraction_model: "anthropic/claude-sonnet-4.5"
----
-
-## Content
-
-ANAD (professional organization) guidance on GLP-1 medications and eating disorders.
-
-**Overall position:** "If you have a current or past eating disorder, please approach these medications with extreme caution and ensure you are working closely with a healthcare provider who understands eating disorders."
-
-**Evidence assessment:** "We simply do not know if these medications will improve, worsen, or have no impact on eating disorder behaviors." Long-term safety/effectiveness "especially for those with an eating disorder — remain unclear."
-
-**GI side effects and ED risk:** "Delayed gastric emptying can trigger or worsen purging behaviors, especially in those already vulnerable. Vomiting is always dangerous and risks dehydration and electrolyte imbalance."
-
-**Poison control:** GLP-1 overdose calls have "tripled in recent years" — misuse pattern, not ED development.
-
-**Recommended screening BEFORE prescribing (no regulatory force):**
-- ED history including type, severity, stage of recovery, coexisting medical/mental health issues, past treatments
-- Screen for: current restrictive eating behaviors, active bingeing or purging, severe body image issues, unstable recovery
-
-**No quantitative incidence data provided** — "long-term research has yet to be done."
-
-**Multidisciplinary approach recommended:** Physician + therapist + dietitian all versed in both GLP-1s and eating disorders before prescribing.
-
-## Agent Notes
-
-**Why this matters:** ANAD is the authoritative professional society for eating disorders. Their guidance is the current clinical standard — and it's recommendation-only with zero regulatory force. The gap between recommended practice (tri-specialist team) and actual practice (no screening required, telehealth prescribing without any evaluation) is the operational measurement of the structural failure.
-
-**What surprised me:** ANAD's epistemic honesty: "We simply do not know" is a strong acknowledgment of the evidence gap. This is the national professional society saying they don't have enough evidence to make a clear recommendation — which itself tells you something about the state of the field.
-
-**What I expected but didn't find:** Any quantitative screening validation data. The SCOFF questionnaire and other screening tools exist but ANAD doesn't provide validation metrics here.
-
-**KB connections:** [[SDOH interventions show strong ROI but adoption stalls because Z-code documentation remains below 3% and no operational infrastructure connects screening to action]] — exact parallel: ED screening is recommended, no reimbursement, no operational pathway.
-
-**Extraction hints:** (1) ANAD recommendation vs. regulatory reality gap is itself a structural governance claim, (2) "Delayed gastric emptying can trigger or worsen purging in those already vulnerable" — confirms the "existing cycles" framing (not de novo), (3) Tri-specialist team recommendation as benchmark for what adequate clinical screening looks like.
-
-**Context:** ANAD is the primary US professional and advocacy organization for eating disorders. Guidance is current as of 2026.
-
-## Curator Notes
-
-PRIMARY CONNECTION: [[SDOH interventions show strong ROI but adoption stalls because Z-code documentation remains below 3 percent and no operational infrastructure connects screening to action]]
-
-WHY ARCHIVED: ANAD guidance formalizes what "best practice" looks like (tri-specialist team + behavioral history) vs. what actually happens (no screening). The gap between recommended and actual practice is the operational measurement of the screening failure.
-
-EXTRACTION HINT: The ANAD guidance + regulatory gap can support a structural claim: GLP-1 prescribing without mandatory ED screening creates population-scale risk because recommended practice (tri-specialist evaluation) has no enforcement mechanism or reimbursement pathway.